C-Terminal Endostatin Peptides for Fibrosis Treatment
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current therapies for organ fibrosis are inadequate, as excessive deposition of extracellular matrix components leads to end-stage organ failure, and existing treatments, such as monoclonal anti-TGF-β antibodies, have shown limited efficacy.
Innovation Solution
C-terminal endostatin polypeptides, specifically comprising amino acids 133-180 of SEQ ID NO: 2, 13, or 4, with optional modifications like amidation, are used to inhibit fibrosis by targeting the underlying pathways involved in fibrosis without affecting angiogenesis.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If monoclonal anti-TGF-β antibodies are used to treat fibrosis, then some therapeutic effect is achieved, but the efficacy is limited and insufficient
Solution Approach 1:
The invention segments the endostatin protein into specific C-terminal fragments (amino acids 133-180) that retain anti-fibrotic activity. This segmentation allows isolation of the most effective region for treating fibrosis while reducing complexity and potential off-target effects of full-length proteins or broader antibodies.
Solution Approach 2:
The invention changes the molecular parameter from full-length endostatin (183 amino acids) to a specific C-terminal fragment (amino acids 133-180). This parameter change optimizes the therapeutic agent for fibrosis treatment by focusing on the region with highest anti-fibrotic activity while maintaining selectivity.
2Reliability
If full-length endostatin is used, then anti-angiogenic activity is achieved, but it may affect normal angiogenesis processes
Solution Approach 1:
The invention applies local quality by using only the C-terminal fragment (amino acids 133-180) of endostatin that specifically targets fibrotic pathways. This localized approach maintains anti-fibrotic efficacy while potentially reducing off-target effects on normal angiogenesis compared to full-length endostatin.
Solution Approach 2:
By segmenting endostatin into the specific C-terminal region, the invention isolates the anti-fibrotic component from other regions that may have broader anti-angiogenic effects, thereby achieving more selective therapy.
Data Source
AI summary
C-terminal endostatin polypeptides are disclosed herein. Polynucleotides encoding these polypeptide, host cells transformed with the polynucleotides, and methods of using these polypeptides and polynucleotides are disclosed. Uses of these polypeptide, polynucleotides and expression vectors include the treatment of fibrosis in a subject. Thus, methods are provided for treating fibrosis, including fibrosis of the skin and/or the lung.